BRL 502
Alternative Names: BRL-502Latest Information Update: 04 Jan 2024
At a glance
- Originator BRL Medicine
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gastric cancer
Most Recent Events
- 19 Dec 2023 Preclinical trials in Gastric cancer in China (Parenteral) (Prior to December 2023) (BRL Medicine Pipeline, December 2023)